Prelude Therapeutics Inc (PRLD)

Nov 20, 2024

Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD) - MSN

Nov 20, 2024

Nov 17, 2024

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update - MarketBeat

Nov 17, 2024

Nov 13, 2024

Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts - Investing.com

Nov 13, 2024

Nov 13, 2024

PRLD Stock Touches 52-Week Low at $1.1 Amid Market Challenges - Investing.com

Nov 13, 2024

Nov 12, 2024

Prelude Therapeutics (NASDAQ:PRLD) Receives Buy Rating from HC Wainwright - Defense World

Nov 12, 2024

Nov 10, 2024

Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 10, 2024

Nov 09, 2024

Prelude Therapeutics Reports Q3 2024 Results and Clinical Progress - MSN

Nov 09, 2024

Nov 08, 2024

Prelude Therapeutics (NASDAQ:PRLD) Given "Buy" Rating at HC Wainwright - MarketBeat

Nov 08, 2024

Nov 07, 2024

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Nov 07, 2024

Oct 31, 2024

PRLD stock touches 52-week low at $1.32 amid market challenges - Investing.com Australia

Oct 31, 2024

Oct 31, 2024

Prelude Therapeutics’ (PRLD) Buy Rating Reiterated at HC Wainwright - Defense World

Oct 31, 2024

Oct 30, 2024

PRLD stock touches 52-week low at $1.32 amid market challenges By Investing.com - Investing.com South Africa

Oct 30, 2024

Oct 28, 2024

Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts By Investing.com - Investing.com South Africa

Oct 28, 2024

Oct 28, 2024

Prelude Therapeutics (NASDAQ:PRLD) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 28, 2024

Oct 27, 2024

Prelude Therapeutics price target lowered to $1 from $3 at Barclays - Yahoo Finance

Oct 27, 2024

Oct 26, 2024

Prelude Therapeutics Shares Promising Phase 1 Trial Data for PRT3789 at International Symposium - MyChesCo

Oct 26, 2024

Oct 24, 2024

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium - Yahoo Finance

Oct 24, 2024

Oct 24, 2024

PRLD stock touches 52-week low at $1.65 amid market challenges - Investing.com India

Oct 24, 2024

Oct 23, 2024

PRLD stock touches 52-week low at $1.65 amid market challenges By Investing.com - Investing.com South Africa

Oct 23, 2024

Oct 16, 2024

Deal Watch: Lilly Turns To Oblique For Antibody Discovery - Scrip

Oct 16, 2024

Oct 14, 2024

Oncopia Therapeutics and University of Michigan divulge new SMARCA2 and SMARCA4 degradation inducers - BioWorld Online

Oct 14, 2024

Oct 13, 2024

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Sees Significant Decline in Short Interest - MarketBeat

Oct 13, 2024

Oct 11, 2024

Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MyChesCo

Oct 11, 2024

Oct 10, 2024

Prelude Therapeutics Showcases Innovative SMARCA Degrader Programs at Barcelona Symposium - MyChesCo

Oct 10, 2024

Oct 09, 2024

Prelude Therapeutics shares updates on cancer drug trials By Investing.com - Investing.com Canada

Oct 09, 2024

Oct 09, 2024

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium - Yahoo Finance

Oct 09, 2024

Oct 04, 2024

Wall Street today: US stocks trade higher as investors re-evaluate big Fed rate cut potential, Intel Corp. gains 1.83% - MSN

Oct 04, 2024

Sep 29, 2024

Short Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Increases By 37.0% - MarketBeat

Sep 29, 2024

Sep 29, 2024

Invesco S&P SmallCap Materials ETF (NASDAQ:PSCM) Short Interest Up 22.6% in September - Defense World

Sep 29, 2024

Sep 29, 2024

RF Acquisition Corp. (NASDAQ:RFAC) Short Interest Update - Defense World

Sep 29, 2024

Sep 29, 2024

Squarepoint Ops LLC Grows Stock Holdings in Teleflex Incorporated (NYSE:TFX) - Defense World

Sep 29, 2024

Sep 29, 2024

Axa S.A. Acquires 1,964 Shares of West Pharmaceutical Services, Inc. (NYSE:WST) - Defense World

Sep 29, 2024

Sep 28, 2024

Employees Retirement System of Texas Makes New Investment in Nova Ltd. (NASDAQ:NVMI) - Defense World

Sep 28, 2024

Sep 23, 2024

FDA Issues Draft Guidance on Multiregional Clinical Trials in Oncology - MyChesCo

Sep 23, 2024

Sep 23, 2024

Firstsource Acquires Ascensos - MENAFN.COM

Sep 23, 2024

Sep 23, 2024

Firstsource acquires UK-based Ascensos for $56 million - The Economic Times

Sep 23, 2024

Sep 21, 2024

Angel Capital weaves passage to glory in Guineas Prelude - Horse Betting

Sep 21, 2024

Sep 21, 2024

Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MyChesCo

Sep 21, 2024

Sep 20, 2024

19 Sundance Movies to Watch Before Seeing These Filmmakers’ New Fall 2024 Releases - Sundance Institute

Sep 20, 2024

Sep 20, 2024

First Taste: At Prelude, Southern-inspired flavors get the fine-dining spotlight. - 7x7

Sep 20, 2024

Sep 20, 2024

Prelude Therapeutics (NASDAQ:PRLD) Upgraded to Strong-Buy by HC Wainwright - MarketBeat

Sep 20, 2024

Sep 19, 2024

Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MyChesCo

Sep 19, 2024

Sep 18, 2024

Data clang on Street for Prelude but SMARCA2 overtures continue - BioWorld Online

Sep 18, 2024

Sep 18, 2024

Healthy Upside Potential: Prelude Therapeutics Inc (PRLD) - SETE News

Sep 18, 2024

Sep 17, 2024

Prelude Therapeutics Inc (PRLD) deserves closer scrutiny - US Post News

Sep 17, 2024

Sep 17, 2024

Prelude Therapeutics (NASDAQ:PRLD) Receives “Market Outperform” Rating from JMP Securities - Defense World

Sep 17, 2024

Sep 16, 2024

A Closer Look at Prelude Therapeutics Inc (PRLD) Stock Gains - The InvestChronicle

Sep 16, 2024

Sep 16, 2024

Glioblastoma Treatment Drugs, Pipeline Insights, Emerging Therapies, and Companies 2024 - openPR

Sep 16, 2024

Sep 16, 2024

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate - Simply Wall St

Sep 16, 2024